
|Articles|March 23, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 3
- Volume 18
- Issue 3
Champions strikes deal with Concordia
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
Advertisement
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.
Articles in this issue
about 17 years ago
Genetics opens new window on acute myeloid leukemiaabout 17 years ago
Pralatrexate: Upfront Rx strategy for T-cell lymphomaabout 17 years ago
Who's Newsover 17 years ago
Functional MRI boosts early staging of cervical cancerover 17 years ago
Unseen bone lesions flare up on post-Rx NSCLC scansover 17 years ago
Exercise jumpstarts quality of life in lung caover 17 years ago
Oncolytics kicks off reovirus trialover 17 years ago
PET/CT picks up additional lesions not found on chest CTover 17 years ago
Targeted therapies address hard-to-treat liver tumorsAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5













































































